ISEE · Iveric Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $50.91M | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $117.01M | $85.07M | $62.78M | $39.64M | $41.74M | $66.29M |
| SG&A | $72.89M | $29.69M | $25.95M | $21.63M | $23.61M | $35.68M |
| Total Operating Expenses | $189.91M | $114.76M | $88.74M | $61.27M | $65.35M | $101.97M |
| D&A | $138.0K | $39.0K | $143.0K | $162.0K | $183.0K | $2.76M |
| Operating Income | ($189.91M) | ($114.76M) | ($88.74M) | ($61.27M) | ($65.35M) | $108.00M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | ($3.69M) | ($111.0K) | ($1.06M) | ($4.71M) |
| Net Income | ($185.21M) | ($114.52M) | ($84.55M) | ($58.86M) | $63.09M | $114.20M |
| EPS - Basic | ($1.53) | ($1.12) | ($1.14) | ($1.39) | $1.70 | ($5.45) |
| EPS - Diluted | ($1.53) | ($1.12) | ($1.14) | ($1.39) | $1.70 | ($5.45) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $476.30M | $261.45M | $66.37M | $125.70M | $131.20M | $166.97M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $662.83M | $387.49M | $216.60M | $128.62M | $133.29M | $171.50M |
| Total Assets | $666.82M | $389.36M | $216.75M | $130.19M | $137.16M | $175.58M |
| Current Liabilities | $35.59M | $28.21M | $25.13M | $12.98M | $13.21M | $12.54M |
| Long-term Debt | $96.57M | - | - | - | - | - |
| Total Liabilities | $132.17M | $28.83M | $25.19M | $12.98M | $13.21M | $137.53M |
| Stockholders' Equity | $534.66M | $360.53M | $191.56M | $117.20M | $123.96M | $38.04M |
| Retained Earnings | ($864.81M) | ($679.60M) | ($565.07M) | ($480.53M) | ($421.67M) | ($484.75M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($163.77M) | ($98.56M) | ($66.10M) | ($48.49M) | ($41.91M) | ($108.60M) |
| Investing Cash Flow | ($50.28M) | $21.30M | ($143.81M) | $150.0K | $0 | $13.73M |
| Financing Cash Flow | $428.90M | $272.33M | $150.58M | $42.84M | $6.14M | $6.93M |
| CapEx | $736.0K | $0 | - | - | $0 | $0 |
| Free Cash Flow | ($164.51M) | ($98.56M) | - | - | ($41.91M) | ($108.60M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -128.4% | - |
| EBITDA margin | - | - | - | - | -128.0% | - |
| Net margin | - | - | - | - | 123.9% | - |
| Free cash flow margin | - | - | - | - | -82.3% | - |
| FCF / Net income | 0.89 | 0.86 | - | - | -0.66 | -0.95 |
| R&D / Revenue | - | - | - | - | 82.0% | - |
| SG&A / Revenue | - | - | - | - | 46.4% | - |
| Effective tax rate | - | - | - | - | -1.7% | -4.3% |
| Return on assets | -27.8% | -29.4% | -39.0% | -45.2% | 46.0% | 65.0% |
| Return on equity | -34.6% | -31.8% | -44.1% | -50.2% | 50.9% | 300.2% |
| Return on invested capital | -23.8% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 18.63 | 13.74 | 8.62 | 9.91 | 10.09 | 13.68 |
| Quick ratio | 18.63 | 13.74 | 8.62 | 9.91 | 10.09 | 13.68 |
| Cash ratio | 13.38 | 9.27 | 2.64 | 9.68 | 9.93 | 13.32 |
| Leverage | ||||||
| Debt / Equity | 0.18 | - | - | - | - | - |
| Debt / Assets | 0.14 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.25 | 1.08 | 1.13 | 1.11 | 1.11 | 4.62 |
| Liabilities / Assets | 0.20 | 0.07 | 0.12 | 0.10 | 0.10 | 0.78 |
| Efficiency | ||||||
| Asset turnover | - | - | - | 0.00 | 0.37 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | -100.0% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -65.5% | -29.3% | -44.8% | 6.2% | - | - |
| Net income growth (YoY) | -61.7% | -35.5% | -43.6% | - | -44.8% | - |
| EPS growth (YoY) | -36.6% | 1.8% | 18.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -66.9% | - | - | - | 61.4% | 0.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 48.3% | 88.2% | 63.4% | -5.5% | 225.9% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IVERIC bio against the 5 most active filers in the same SIC group.